Eosinophil Morphological Observation: Staining Basis, Identification Points, and Research Validation
Eosinophil Morphological Observation: Staining Basis, Identification Points, and Research Validation
Eosinophils are an important leukocyte type within the granulocytic lineage. They are mainly involved in the pathological processes of parasitic infection, allergic reactions, asthma, drug reactions, autoimmune inflammation, and certain hematologic diseases. Morphological observation can directly evaluate eosinophil number, maturation status, granule morphology, nuclear segmentation, and abnormal changes. It is an important component of peripheral blood smear examination, bone marrow smear analysis, body fluid cytology, and tissue infiltration assessment.
Keywords: eosinophils; morphological observation; blood smear; bone marrow smear; Romanowsky staining; Wright staining; Giemsa staining; eosinophilic granules; EPX; ECP; CCR3; IL-5
1、Basic Logic of Eosinophil Morphological Observation
1.1 Observation targets
(1) Mature eosinophils
Mature eosinophils are usually seen in peripheral blood smears and are slightly larger than mature neutrophils. Their typical features include a bilobed or segmented nucleus and cytoplasm filled with coarse, uniform, orange-red to brick-red specific granules. The cell boundary is relatively clear, and the cytoplasmic background is usually pale blue or pale pink.
(2) Immature eosinophils
Immature eosinophils are mainly observed in bone marrow smears, including eosinophilic myelocytes, metamyelocytes, and band forms. Identification requires combined evaluation of chromatin maturation, cytoplasmic volume, nuclear shape changes, and the degree of eosinophilic granule formation. In early stages, granules may not be fully typical, and distinction from the neutrophilic lineage and abnormal granular cells is required.
(3) Abnormal eosinophils
Abnormal eosinophils may show reduced granules, uneven granule size, abnormal granule staining, abnormal nuclear segmentation, vacuole formation, or abnormal cytoplasmic development. These changes may be seen in reactive eosinophilia, clonal eosinophilia, and some myeloid neoplasms.
1.2 Purposes of morphological observation
(1) Confirming cell type
The first purpose of eosinophil morphological observation is accurate identification during leukocyte differential counting. Typical eosinophilic granules are the most important morphological basis, but nuclear shape, cytoplasmic background, and overall smear staining quality should also be considered.
(2) Assessing maturation stage
In bone marrow samples, eosinophils may be present at different maturation stages. Nuclear chromatin, nuclear shape, granule formation, and cytoplasmic ratio can help determine whether eosinophil development is continuous, whether maturation is blocked, or whether abnormal proliferation is present.
(3) Suggesting pathological background
An increased eosinophil percentage alone cannot determine the cause. If morphological abnormalities, increased eosinophilic precursor cells in bone marrow, abnormal granules, or accompanying abnormalities in other blood cells are present, immunophenotyping, cytogenetic testing, or molecular testing should be considered.
Table 1 Core Elements in Eosinophil Morphological Observation
Observation item | Main content | Interpretive significance | Notes |
Cell size | Whether slightly larger than neutrophils | Helps identify mature eosinophils | Affected by smear thickness and cell spreading |
Nucleus | Bilobed, segmented, or band-shaped nucleus | Assesses maturation and nuclear abnormalities | Nuclear shape alone is insufficient for identification |
Cytoplasmic granules | Orange-red, coarse, relatively uniform granules | Most important identification feature of eosinophils | Staining conditions may affect color intensity |
Cytoplasmic background | Pale blue, pale pink, or light background | Helps distinguish maturation stage | Difficult to observe when granules are dense |
Granule distribution | Uniform or abnormally concentrated | Assesses granule maturation and abnormalities | Staining precipitates must be excluded |
Accompanying cellular changes | Neutrophils, basophils, blasts, etc. | Helps distinguish reactive or clonal background | Should be interpreted with the whole smear and count results |
2、Staining Methods and Basis of Microscopic Observation
2.1 Romanowsky-type staining
(1) Wright staining
Wright staining is commonly used for eosinophil observation in peripheral blood smears and bone marrow smears. Eosinophilic granules usually appear orange-red or red, while nuclei appear bluish purple to purplish red. It is suitable for routine leukocyte differential counting and assessment of granulocyte maturation stages.
(2) Giemsa staining
Giemsa staining provides good visualization of nuclear chromatin and some parasite structures, and it can also be used for eosinophil observation. Granule color may differ slightly from that seen in Wright staining, so interpretation should follow the staining system and laboratory standards.
(3) Wright-Giemsa staining
Wright-Giemsa staining combines overall blood cell morphology with nuclear and cytoplasmic detail. It is suitable for bone marrow smears, peripheral blood review, and morphological analysis of hematologic diseases. Under this staining system, eosinophilic granules, nuclear segmentation, and cytoplasmic maturation are usually easy to observe.
2.2 HE staining and tissue sample observation
(1) Tissue infiltration observation
In tissue sections, eosinophils are commonly observed using HE staining. Their cytoplasmic granules usually appear strongly eosinophilic, red to orange-red, and can be used to assess eosinophilic infiltration in the skin, gastrointestinal tract, respiratory tract, nasal polyps, and other tissues.
(2) Association with tissue background
HE staining also allows simultaneous observation of tissue structure, inflammatory background, necrosis, fibrosis, and epithelial damage. Unlike blood smears, cells in tissue sections are affected by sectioning direction, and the bilobed nucleus may not always be fully visible. Granule morphology and tissue localization should therefore be considered together.
(3) Application boundaries
HE staining is suitable for tissue-level infiltration assessment but is less suitable than blood or bone marrow smears for detailed evaluation of granulocyte maturation stages. If eosinophil-associated proteins need to be confirmed, immunostaining for markers such as EPX and ECP can be performed.
2.3 Effects of staining conditions
(1) pH effect
Romanowsky-type staining is sensitive to buffer pH. When pH is too low, the smear may appear overly red, eosinophilic granules may appear excessively strong, and leukocyte nuclear staining may be pale. When pH is too high, the background becomes bluish, and red blood cell and cytoplasmic colors become abnormal, which may affect interpretation of eosinophilic granules.
(2) Staining time
Insufficient staining can make both granules and nuclei pale, resulting in unclear eosinophilic granules. Overstaining deepens the background and reduces contrast between nuclei and granules. Eosinophil morphology should be evaluated in areas with uniform staining and normal red blood cell background.
(3) Smear quality
If the smear is too thick, cell overlap and granule accumulation may cause misinterpretation. If the smear is too thin, cells may be distorted or insufficiently distributed. Mature eosinophils should be assessed in the monolayer region near the junction between the body and tail of the blood film.
Table 2 Common Staining Methods for Eosinophil Observation
Staining method | Granule display characteristics | Applicable samples | Main uses |
Wright staining | Granules usually appear orange-red to red | Peripheral blood, bone marrow | Leukocyte differential count, granulocyte morphology |
Giemsa staining | Clear nuclear staining, granules visible | Blood smears, bone marrow, parasite-related samples | Parasite background and nuclear-cytoplasmic structure observation |
Wright-Giemsa staining | Balanced nuclear-cytoplasmic contrast and granule display | Peripheral blood, bone marrow | Comprehensive blood cell morphology analysis |
May-Grünwald-Giemsa staining | Rich cellular layering | Bone marrow, cytology smears | Cytology and bone marrow morphology observation |
Diff-Quik staining | Rapid staining, slightly limited detail | Cytology smears, rapid assessment samples | Screening and on-site morphological evaluation |
HE staining | Eosinophilic granules appear red to orange-red | Tissue sections | Tissue infiltration, inflammatory background, and tissue structure observation |
3、Morphological Features of Mature Eosinophils
3.1 Cell size and outline
(1) Cell size
Mature eosinophils are usually about 12–17 μm in diameter and are slightly larger than mature neutrophils. Cell size may be affected by smear spreading, so it cannot be used as the sole identification criterion.
(2) Cell outline
The cell outline is usually round and well defined. Poor smear preparation, prolonged sample storage, or cell damage may cause cytoplasmic granules to leak out, resulting in unclear cell boundaries or free granules.
(3) Cytoplasmic status
The cytoplasm is mostly occupied by coarse eosinophilic granules, and its background color is less obvious than that of lymphocyte cytoplasm. When granules are dense, the cytoplasmic ground color may be obscured, requiring interpretation based on nuclear shape and granule color.
3.2 Nuclear characteristics
(1) Typical bilobed nucleus
The most typical nuclear shape of a mature eosinophil is a bilobed nucleus, with the two lobes connected by a thin chromatin strand. The nuclear chromatin is mature, deeply stained, and relatively coarse.
(2) Segmented nucleus
Some mature eosinophils may have more than two nuclear lobes, but their segmentation is usually less complex than that of neutrophils. If excessive segmentation or obvious nuclear abnormalities are present, other cellular abnormalities should be considered when assessing pathological significance.
(3) Band-shaped or incompletely segmented nucleus
Band-shaped or incompletely segmented eosinophils may occasionally be seen in peripheral blood. If their proportion is clearly increased, increased bone marrow release, reactive proliferation, or a myeloid abnormality should be considered.
3.3 Cytoplasmic granule characteristics
(1) Color
Eosinophilic granules are usually orange-red, red, or brick-red and are the key feature for identifying mature eosinophils. Granule color is strongly influenced by the staining system and pH; smears that are globally too red or too blue are unsuitable for fine color interpretation.
(2) Size
Mature eosinophilic granules are coarser than neutrophil granules and are usually relatively uniform. Abnormally coarse, uneven, or clearly sparse granules should raise concern for abnormal eosinophils.
(3) Distribution
Normal mature eosinophilic granules are diffusely distributed in the cytoplasm and should not completely obscure the nucleus. Granule aggregation, degranulation, or obvious cytoplasmic vacuoles should be interpreted in relation to sample preservation, inflammatory status, and pathological background.
Table 3 Typical Morphology of Mature Eosinophils
Morphological item | Typical appearance | Interpretive value | Common confounding factors |
Cell size | Slightly larger than neutrophils | Auxiliary identification | Differences in smear spreading |
Nucleus | Bilobed nucleus common | Identifies mature eosinophils | Segmented neutrophil nuclei |
Chromatin | Coarse and mature | Distinguishes immature stages | Pale nuclei due to insufficient staining |
Cytoplasmic granules | Coarse, orange-red, relatively uniform | Main identification basis | Stain precipitates, granule leakage |
Cytoplasmic background | Pale blue or pale pink | Auxiliary observation | Not obvious when granules are too dense |
Cell boundary | Relatively clear | Assesses cellular integrity | Prolonged storage or smear damage |
4、Maturation Stages of Eosinophils in Bone Marrow
4.1 Eosinophilic myelocytes
(1) Nuclear shape and chromatin
The nucleus of eosinophilic myelocytes is usually round, oval, or mildly indented. Chromatin is coarser than in blasts but not fully mature. Nucleoli are usually not prominent or gradually disappear.
(2) Cytoplasmic granules
More obvious eosinophilic granules begin to appear in the cytoplasm. These granules may be relatively coarse but not yet completely uniform in distribution. This stage is important for recognizing eosinophilic differentiation.
(3) Key interpretation points
Eosinophilic myelocytes should be distinguished from neutrophilic myelocytes and abnormal granular cells. If eosinophilic granules appear early, are coarse, and coexist with immature nuclear development, the overall granulocytic development in bone marrow should be evaluated.
4.2 Eosinophilic metamyelocytes
(1) Nuclear shape changes
The nucleus of eosinophilic metamyelocytes becomes eccentric and may appear kidney-shaped or indented. Chromatin becomes more condensed. Compared with myelocytes, the nuclear-cytoplasmic ratio decreases.
(2) Granule maturation
Eosinophilic granules become more abundant and their color becomes closer to that of mature eosinophils. Granules are widely distributed and are often the main basis for identifying this stage.
(3) Morphological significance
An increased metamyelocyte stage in bone marrow can be seen in reactive eosinophilic proliferation and in some myeloid neoplasms. Blast proportion, other granulocytic development, and erythroid-megakaryocytic changes should be assessed simultaneously.
4.3 Eosinophilic band cells and segmented cells
(1) Band stage
The nucleus is band-shaped, curved, or rod-like, with dense coarse chromatin and mature cytoplasmic granules. This stage is an important form before mature eosinophil release from bone marrow.
(2) Segmented stage
Segmented eosinophils resemble mature cells seen in peripheral blood. When the proportion of mature eosinophils increases in bone marrow, it should be determined whether this is part of overall eosinophilic proliferation.
(3) Maturation continuity
In normal or reactive proliferation, eosinophils usually show continuous maturation across stages. If one stage is abnormally accumulated, development appears asynchronous, or blasts are increased, abnormal hematopoiesis should be considered.
Table 4 Interpretation of Eosinophil Maturation Stages in Bone Marrow
Maturation stage | Nuclear features | Granule features | Interpretation focus |
Eosinophilic myelocyte | Round, oval, or mildly indented | Eosinophilic granules begin to appear clearly | Identifying eosinophilic differentiation |
Eosinophilic metamyelocyte | Indented, eccentric nucleus; coarser chromatin | Increased granules and stronger color | Assessing continuity of maturation |
Eosinophilic band cell | Band-shaped or rod-like nucleus | Relatively mature granules | Evaluating the pre-release stage |
Eosinophilic segmented cell | Bilobed or segmented nucleus | Coarse orange-red granules | Corresponds to mature eosinophils |
Abnormal eosinophilic precursor | Asynchronous nuclear-cytoplasmic development | Abnormal or uneven granules | Requires screening for clonal disease |
5、Morphological Observation in Eosinophilia
5.1 Reactive eosinophilia
(1) Common backgrounds
Reactive eosinophilia may occur in allergic diseases, asthma, parasitic infection, drug reactions, skin diseases, rheumatic and autoimmune diseases, and certain post-infectious states. Morphologically, it is usually dominated by increased mature eosinophils.
(2) Morphological features
In reactive eosinophilia, eosinophils are mostly regular in morphology, with clear bilobed nuclei and coarse orange-red granules. Mild activation changes may be seen, such as uneven granule distribution, mild degranulation, or cytoplasmic vacuoles, but obvious atypia is usually absent.
(3) Interpretation approach
Reactive eosinophilia should be interpreted with absolute eosinophil count, clinical history, medication history, allergy markers, parasite testing, and other inflammatory indicators. Morphology alone cannot determine the exact trigger.
5.2 Clonal eosinophilia
(1) Suggestive clues
If eosinophilia is accompanied by marked leukocytosis, anemia, platelet abnormalities, splenomegaly, increased blasts, obvious bone marrow proliferation, or other granulocytic abnormalities, a clonal disorder should be considered.
(2) Morphological abnormalities
In a clonal background, eosinophils may show reduced granules, uneven granule size, abnormally coarse granules, abnormal nuclear segmentation, nuclear-cytoplasmic developmental asynchrony, or an abnormal proportion of immature eosinophilic cells. Some cases may also show basophilia or other myeloid abnormalities.
(3) Follow-up testing
Morphology provides only clues. Suspected clonal eosinophilia should be further confirmed by bone marrow examination, flow cytometry, karyotyping, FISH, fusion gene testing, and related assays.
5.3 Hypereosinophilic states
(1) Key points in morphological observation
In hypereosinophilic states, attention should be paid to the proportion and absolute count of mature eosinophils in peripheral blood, the presence of immature cells, accompanying abnormalities in other leukocytes, and whether eosinophilic differentiation in bone marrow is continuous.
(2) Association with tissue injury
Eosinophilia may be associated with tissue infiltration and organ damage, but smear morphology cannot directly assess the extent of tissue injury. If cardiac, pulmonary, cutaneous, gastrointestinal, or nervous system manifestations are present, clinical and histological evaluation is required.
(3) Dynamic monitoring
Morphological observation can be used to monitor changes in eosinophil proportion and morphology before and after model treatment, stimulation experiments, or interventions. If abnormal morphology persists after changes in eosinophil number, possible clonal disease, sustained activation, or experimental-condition effects should be considered.
Table 5 Morphological Clues in Eosinophilia
Type | Morphological features | Common accompanying findings | Follow-up direction |
Reactive eosinophilia | Mostly mature forms with regular granules | Allergy, infection, drug exposure, inflammatory background | Clinical history and laboratory indicators |
Parasite-related eosinophilia | Increased mature eosinophils | May be accompanied by elevated total IgE or tissue symptoms | Parasitological and serological testing |
Drug reaction-related eosinophilia | May show mild activation or degranulation | Rash, fever, liver or kidney injury | Medication history and systemic assessment |
Clonal eosinophilia | Granule abnormalities, nuclear abnormalities, increased immature cells | Leukocytosis, splenomegaly, anemia, or platelet abnormalities | Bone marrow, genetic, and molecular testing |
Hypereosinophilic state | Marked increase, possibly with abnormal morphology | Organ involvement or tissue infiltration | Clinical classification and mechanism testing |
6、Abnormal Eosinophil Morphology
6.1 Granule abnormalities
(1) Reduced granules
Reduced granules appear as sparse eosinophilic granules in the cytoplasm, making cell identification more difficult. This should be distinguished from insufficient staining, degranulation, and smear damage.
(2) Uneven granule size
Markedly variable granule size may suggest abnormal development or a clonal background, but smear quality and staining conditions can also contribute. Repeated observation across multiple cells is required before interpretation.
(3) Degranulation
Degranulation appears as reduced cytoplasmic granules, granule leakage, or scattered red granules around the cell. It may occur in activated cells, poorly preserved samples, or mechanically damaged smears, and should be interpreted with the overall smear background.
6.2 Nuclear abnormalities
(1) Hyposegmentation or abnormal segmentation
Insufficient nuclear segmentation, irregular nuclear shape, or abnormal chromatin connections may be seen in dysplasia or reactive change. If other granulocytic abnormalities are also present, myelodysplasia or myeloid clonal disease should be considered.
(2) Hypersegmentation
Hypersegmented eosinophils are uncommon and should be distinguished from neutrophils. Granule color and size remain key distinguishing features.
(3) Nuclear-cytoplasmic developmental asynchrony
An immature nucleus with mature granules, or a mature nucleus with abnormal cytoplasm, suggests developmental asynchrony. This finding is more meaningful in bone marrow smears.
6.3 Cytoplasmic abnormalities
(1) Vacuole formation
Cytoplasmic vacuoles may be seen in cellular activation, poor sample preservation, or abnormal cellular states. A small number of vacuoles may have limited significance, while extensive vacuolization should be interpreted in relation to infection, inflammation, or cell injury.
(2) Increased cytoplasmic basophilia
Immature eosinophils or activated cells may show bluer cytoplasm. If granules are also atypical, distinction from basophils, abnormal monocytes, or immature granulocytes is required.
(3) Cell fragmentation
Cell fragmentation may produce free eosinophilic granules, which can be mistaken for background precipitates or microbial structures. Interpretation should assess whether the granules are associated with cell remnants and exclude smear preparation damage.
Table 6 Abnormal Eosinophil Morphology and Significance
Abnormal feature | Morphological characteristics | Possible implication | Interpretation notes |
Reduced granules | Sparse cytoplasmic granules | Developmental abnormality, degranulation, insufficient staining | Technical factors must be excluded |
Uneven granule size | Obvious differences in size and color | Abnormal development or clonal background | Repeated observation in multiple cells required |
Granule leakage | Scattered red granules around cells | Cell activation or smear damage | Note sample storage time |
Abnormal nuclear segmentation | Hyposegmentation, irregular segmentation | Dysplasia or reactive change | Interpret with other granulocytic morphology |
Nuclear-cytoplasmic asynchrony | Nuclear and granule maturation are discordant | Possible myeloid abnormality | More meaningful in bone marrow |
Cytoplasmic vacuoles | Obvious cytoplasmic vacuoles | Activation, injury, or abnormal state | Interpret with whole-smear background |
Cytoplasmic fragmentation | Incomplete cellular structure | Smear damage or increased cell fragility | Should not be used alone as disease evidence |
7、Product Selection for Eosinophil Morphological Observation
Table 7 Staining Solutions and Kits Related to Eosinophil Morphological Observation
Cat. No. | Product Name | Grade/Purity/Specification | Product Category | Applicable observation scenario | Methodological application positioning |
Eosinophil Staining Solution | BioReagent,Biological Stain,for microscopy | Specific staining solution | Eosinophil morphological observation | Directly corresponds to eosinophil observation and is the core staining solution in this article | |
Wright Stain Solution (ready-to-use) | ready-to-use,Biological Stain,Suitable for microbiology,for microscopy,BioReagent | Romanowsky-type ready-to-use stain | Peripheral blood smear; bone marrow smear | Used for leukocyte differential count and observation of eosinophil granules, nuclear shape, and maturation status | |
Wright Staining Kit | BioReagent, Biological Stain, for microscopy | Romanowsky-type ready-to-use kit | Peripheral blood smear; bone marrow smear | Standardized Wright staining workflow, suitable for routine hematologic cytomorphology | |
Wright-Giemsa Staining Kit | BioReagent, Biological Stain, for microscopy | Romanowsky-type ready-to-use kit | Peripheral blood smear; bone marrow smear | Suitable for simultaneous observation of eosinophilic granules, chromatin, granulocytic maturation stages, and accompanying blood cell abnormalities | |
Giemsa Staining Solution | BioReagent, Biological Stain, for microscopy, 10X | Romanowsky-type ready-to-use stain | Blood smear; bone marrow smear; parasite-related samples | Used for eosinophil and other leukocyte morphology observation; also suitable for morphological review in parasite-associated backgrounds | |
Giemsa Staining Solution (Ready-to-use) | BioReagent,ready-to-use,Biological Stain,Suitable for microbiology,for microscopy | Romanowsky-type ready-to-use stain | Blood smear; bone marrow smear; some microbiology-related samples | Suitable for rapid establishment of Giemsa staining workflow for leukocyte nuclear-cytoplasmic structures and eosinophilic granules | |
May-Grunwald Stain Solution | BioReagent,Biological Stain,for microscopy,Suitable for microbiology | May-Grünwald staining solution | Bone marrow smear; cytology smear; MGG system | Used in the first stage of May-Grünwald-Giemsa staining to help display cytoplasmic background and nuclear-cytoplasmic layering | |
Diff-Quik Staining Solution | BioReagent, for microscopy, Biological Stain | Rapid Romanowsky-type stain | Rapid cytology evaluation; aspiration smear; rapid morphological observation | Used for rapid display of eosinophil granules and leukocyte morphology, suitable for screening or on-site evaluation | |
Diff-Quik Stain (Fixative-Free) | BioReagent,Bioactive,for microscopy | Rapid Romanowsky-type stain | Already fixed smears; rapid cytology staining | Suitable for rapid morphological staining when fixation has already been performed or needs to be independently controlled | |
Hematoxylin-Eosin (HE) High-Definition Consistent Staining Kit (High-Definition Stable Staining) | BioReagent,for microscopy,Biological Stain | HE tissue staining kit | Eosinophil infiltration observation in tissue sections | Suitable for observing eosinophilic infiltration, inflammatory background, and tissue structural changes in histopathology | |
Hematoxylin-Eosin (HE) Staining Kit (with Differentiating Solution) | BioReagent,for microscopy,Biological Stain | HE tissue staining kit | Tissue sections | Used to identify eosinophils and inflammatory infiltration areas in routine HE-stained tissue sections | |
Hematoxylin-Eosin (HE) Staining Kit (with Differentiating Solution and Bluing Solution) | BioReagent,for microscopy,Biological Stain | HE tissue staining kit | Tissue sections | Complete differentiation and bluing steps, suitable for simultaneous observation of tissue structure and inflammatory cell morphology | |
Modified Hematoxylin-Eosin (HE) Staining Kit | BioReagent,for cell culture,for microscopy | Modified HE staining kit | Tissue sections; cultured cell samples | Can be used to observe eosinophilic staining background in tissue or cell samples; not preferred for peripheral blood smears | |
Ematoxylin-Eosin Stain |
| HE ready-to-use stain | Tissue sections | Used for tissue-section observation of eosinophil infiltration and histopathological background | |
Eosin Staining Solution | 5%(w/v) | Acidic dye component | HE staining; Romanowsky system component | Eosin-type acidic dye can stain eosinophilic granules, red blood cells, and cytoplasmic proteins red to orange-red | |
Eosin Staining Solution (0.5% alcoholic solution ) | BioReagent, Biological Stain, for microscopy, Water Soluble, 0.5% | Acidic dye component | Tissue/cell staining support | Can be used as an aqueous eosin component to explain the staining logic of eosinophilic structures | |
Eosin Staining Solution ( 1% aqueous solution) | BioReagent, Biological Stain, for microscopy, Water Soluble, 1% | Acidic dye component | Tissue/cell staining support | Used for staining cytoplasm, red blood cells, and eosinophilic structures; not a complete leukocyte differential staining system | |
Eosin Staining Solution (0.25% alcoholic solution) | BioReagent, Biological Stain, for microscopy, Alcohol Soluble, 0.25% | Acidic dye component | HE or compound staining support | Can serve as an alcohol-soluble eosin component for explaining eosinophilic granule and cytoplasmic protein staining | |
Eosin Staining Solution (Alcohol-Soluble, 0.5%) | BioReagent,Biological Stain,for microscopy,0.5% | Acidic dye component | HE or compound staining support | Can be used as a component related to eosinophilic structure staining to explain eosin’s role in staining granules and cytoplasm | |
Eosin Staining Solution (1% alcoholic solution ) | Alcohol Soluble, 1% | Acidic dye component | HE or compound staining support | Suitable as an alcohol-soluble eosin component; not an independent method for eosinophil morphological observation | |
Water Soluble Eosin Y Stainin Solution |
| Acidic dye component | Tissue/cell staining support | Supplementary eosin-type acidic dye item for explaining eosinophilic structure staining | |
Alcohol Soluble Eosin Y Stainin Solution |
| Acidic dye component | Tissue/cell staining support | Alcohol-soluble eosin-related product for explaining staining of eosinophilic granules, cytoplasm, and red blood cells | |
Loeffler's Methylene Blue Staining Solution | BioReagent, Biological Stain, for microscopy, 0.6% | Basic thiazine dye component | Romanowsky system component explanation | Used to explain nuclear acid, chromatin, and basophilic structure staining, forming nuclear-cytoplasmic contrast with eosinophilic granule observation | |
Löffler's Methylene Blue Staining Solution (0.1%) | BioReagent,for microscopy,Biological Stain | Basic thiazine dye component | Romanowsky system component explanation | Methylene blue-type dye product for mechanism and component explanation | |
Lv's alkaline methylene blue staining solution (0.23%) | BioReagent,for microscopy,Biological Stain,0.23% | Basic thiazine dye component | Romanowsky system component explanation | Used to explain the role of basic dyes in staining nucleic acids and basophilic structures | |
Löffler's Methylene Blue Staining Solution (0.4%) | BioReagent,Biological Stain,for microscopy,0.4% | Basic thiazine dye component | Romanowsky system component explanation | Methylene blue-type component product used to supplement staining mechanisms for eosinophil nuclear-shape observation | |
Unna Alkaline Methylene Blue Staining Solution | BioReagent,Biological Stain,for microscopy | Basic thiazine dye component | Romanowsky system component explanation | Used to explain the staining logic of alkaline methylene blue-type dyes binding to nucleic acids and acidic cellular components | |
New Methylene Blue Stain Solution | BioReagent,for microscopy,Biological Stain | Thiazine dye-related product | Hematologic staining supplement | Related to thiazine dyes and hematologic staining; may serve as a mechanism supplement but is not a core classic stain for eosinophilic granule observation |
Table 8 Auxiliary Validation and Mechanism Research Products Related to Eosinophil Morphological Observation
Cat. No. | Product Name | Grade/Purity/Specification | Product Category | Related direction | Methodological application positioning |
EPX Human Pre-designed siRNA Set A |
| EPX gene silencing tool | Eosinophil granule protein mechanism research | Used for EPX gene silencing to study regulation of eosinophil peroxidase expression; not a morphology staining product | |
Recombinant Human EPX Protein | ≥90%(SDS-PAGE) | Recombinant EPX protein | Eosinophil granule protein validation | Can serve as positive material for EPX-related antibodies, ELISA, or functional experiments in eosinophil granule protein research | |
Mouse Eosinophil Peroxidase (EPX) ELISA Kit | BioReagent | EPX ELISA kit | Eosinophil activation/degranulation detection | Used for quantitative detection of mouse EPX, supporting evaluation of eosinophil activation or granule protein release | |
Ribonuclease 3/ECP Antibody | Carrier Free, See COA | ECP antibody | Eosinophil cationic protein localization/validation | ECP is an eosinophil granule-associated protein and can be used for immunostaining, protein detection, or degranulation-related research | |
Mouse Eosinophil Cationic Protein (ECP) ELISA Kit | BioReagent | ECP ELISA kit | Eosinophil activation/granule protein detection | Used for mouse ECP quantification, suitable for auxiliary explanation of eosinophil activation and granule protein release | |
Recombinant Human Siglec-8 Protein | Animal Free,Carrier Free,Bioactive,ActiBioPure™,His Tag,≥95%(SDS-PAGE) | Recombinant Siglec-8 protein | Surface marker validation | Used for antibody-binding validation, standards, or mechanistic experiments related to Siglec-8-mediated eosinophil identification | |
CCR3 Human Pre-designed siRNA Set A |
| CCR3 gene silencing tool | Eosinophil chemokine receptor research | CCR3 is an eosinophil chemotaxis-related receptor and can be used for human CCR3 knockdown experiments | |
Ccr3 Mouse Pre-designed siRNA Set A |
| CCR3 gene silencing tool | Mouse eosinophil chemotaxis mechanism | Used for mouse Ccr3 knockdown, suitable for eosinophil migration, chemotaxis, and inflammation model research | |
Ccr3 Rat Pre-designed siRNA Set A |
| CCR3 gene silencing tool | Rat eosinophil chemotaxis mechanism | Used for rat Ccr3 knockdown, suitable for chemokine receptor mechanism research and model validation | |
Recombinant CCR3 Antibody | ExactAb™, Validated, Recombinant, 1.5 mg/mL | CCR3 antibody | Eosinophil surface marker/chemokine receptor | Used for CCR3 protein detection or localization, supporting confirmation of eosinophil-related chemokine receptor expression | |
Mouse Chemokine C-C-Motif Receptor 3 (CCR3) ELISA Kit | BioReagent | CCR3 ELISA kit | Mouse CCR3 quantitative detection | Used for mouse CCR3 level detection, suitable for eosinophil chemotaxis pathway research | |
CCR3 antagonist 1 | ≥98% | CCR3 antagonist | Pharmacological intervention in chemotaxis pathway | Used for CCR3 pathway inhibition experiments, supporting analysis of eosinophil recruitment and migration mechanisms | |
SB 297006 | ≥98% | CCR3 antagonist | Pharmacological intervention in chemotaxis pathway | CCR3 inhibitor for eosinophil chemotaxis-related models | |
SB 328437 | Moligand™, ≥98% | CCR3 antagonist | Pharmacological intervention in chemotaxis pathway | Used for research on CCR3-mediated eosinophil migration and inflammatory responses | |
UCB 35625 | ≥98%(HPLC) | CCR1/CCR3 antagonist | Pharmacological intervention in chemotaxis pathway | Used in CCR3-related chemotaxis experiments; because it also acts on CCR1, receptor specificity must be considered | |
pLenti-CCR3-sgRNA |
| CCR3 knockout validation lysate | CCR3 protein detection control | Can serve as a negative/knockout validation material for CCR3 antibody or protein detection | |
pLenti-CCR3-sgRNA |
| CCR3 knockout validation lysate | CCR3 transcript-level detection control | Can be used for CCR3 gene expression detection or qPCR validation | |
IL-5 | Moligand™ | IL-5 protein | Eosinophil differentiation/activation stimulation | IL-5 pathway stimulant for eosinophil-related cell models or mechanistic research | |
Recombinant Human IL-5 Protein | Animal Free,Carrier Free,Bioactive,ActiBioPure™,High Performance,His Tag,≥95%(SDS-PAGE),expressed in HEK293; See COA | Recombinant human IL-5 protein | Human IL-5 pathway research | Used for human eosinophil differentiation, activation, survival, or signaling research | |
Recombinant Mouse IL-5 Protein | Animal Free,Carrier Free,Bioactive,ActiBioPure™,High Performance,His Tag,≥97%(SDS-PAGE) | Recombinant mouse IL-5 protein | Mouse model/cell experiments | Suitable for mouse eosinophil-related models and IL-5 stimulation experiments | |
Recombinant Rat IL-5 Protein | Animal Free,Carrier Free,Bioactive,ActiBioPure™,High Performance,His Tag,≥97%(SDS-PAGE) | Recombinant rat IL-5 protein | Rat model/cell experiments | Suitable for rat eosinophil-related models and IL-5 stimulation experiments | |
IL-5 Rat mAb | Carrier Free,Azide Free,Validated,PBS Only,≥95%(SDS-PAGE),See COA | IL-5 antibody | IL-5 detection/blocking experiment | Used for IL-5 protein detection or functional blocking experiments | |
Recombinant IL-5 Antibody | Carrier Free,Recombinant,ExactAb™,Azide Free,Validated,PBS Only,See COA | Recombinant IL-5 antibody | IL-5 detection/mechanism research | Used for IL-5 detection, pathway validation, or blocking experiments | |
Recombinant IL-5 Antibody | Carrier Free,Recombinant,ExactAb™,Azide Free,Validated,PBS Only,See COA | Recombinant IL-5 antibody | IL-5 detection/mechanism research | Used for IL-5-related experimental validation | |
Human Interleukin 5 (IL-5) ELISA Kit | BioReagent | IL-5 ELISA kit | Human IL-5 quantitative detection | Used to detect IL-5 levels in eosinophil-related inflammatory backgrounds | |
Rat Interleukin 5 (IL-5) ELISA Kit | BioReagent | IL-5 ELISA kit | Rat IL-5 quantitative detection | Suitable for analyzing the relationship between IL-5 pathway and eosinophilia in rat models | |
Mouse Interleukin 5 (IL-5) ELISA Kit | BioReagent | IL-5 ELISA kit | Mouse IL-5 quantitative detection | Suitable for detecting IL-5 in mouse allergy, asthma, or parasitic infection models | |
Guinea Pig Interleukin 5 (IL-5) ELISA Kit | BioReagent | IL-5 ELISA kit | Guinea pig IL-5 quantitative detection | Used for IL-5-related eosinophilic inflammation research in guinea pig models |
Eosinophil morphological observation should focus on nuclear shape, cytoplasmic granules, maturation stage, and accompanying cellular abnormalities. Mature eosinophils have a typical bilobed nucleus and coarse orange-red granules, but when abnormal increase, granule changes, or increased immature stages are present, results must be interpreted together with peripheral blood counts, bone marrow morphology, clinical background, and molecular genetic testing.
